Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study
Open Access
- 12 November 2015
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (11) , e0142033
Abstract
New therapeutic agents are warranted in idiopathic membranous nephropathy. Synthetic ACTH may be advantageous with reported remission rates up to 85% and few side effects. We conducted a prospective open label cohort study from 2008 till 2010 (NCT00694863). We prospectively selected patients with idiopathic membranous nephropathy and high risk for progression (defined as βeta-2-microglobulin (β2m) excretion of >500 ng/min). For comparison, we selected matched historical controls treated with cyclophosphamide. The prospectively selected patients received intramuscular injections of synthetic ACTH during 9 months (maximal dose 1 mg twice a week). The primary endpoints concerned the feasibility and incidence of remissions as a primary event. Secondary endpoints included side effects of treatment and the incidence of remissions and relapses at long-term follow-up. Twenty patients (15 men) were included (age 54±14 years, serum creatinine 104 μmol/l [IQR 90–113], urine protein:creatinine ratio 8.7 g/10 mmol creatinine [IQR 4.3–11.1]). Seventeen patients (85%) completed treatment. 97% of injections were administered correctly. Cumulative remission rate was 55% (complete remission in 4 patients, partial remission 7 patients). In a group of historical controls treated with cyclophosphamide and steroids, 19 of 20 patients (95%) developed a remission (complete remission in 13 patients, partial remission in 6 patients) (p<0.01). The main limitation of our study is its small size and the use of a historical control group. We show that treatment with intramuscular injections of synthetic ACTH is feasible. Our data suggest that synthetic ACTH is less effective than cyclophosphamide in inducing a remission in high risk patients with idiopathic membranous nephropathy. The use of synthetic ACTH was also associated with many adverse events. Therefore, we advise against synthetic ACTH as standard treatment in membranous nephropathy. ClinicalTrials.gov NCT00694863Keywords
This publication has 23 references indexed in Scilit:
- Low-Molecular-Weight Proteins as Prognostic Markers in Idiopathic Membranous NephropathyClinical Journal of the American Society of Nephrology, 2011
- Alkylating agents in membranous nephropathy: efficacy proven beyond doubtNephrology Dialysis Transplantation, 2010
- M-Type Phospholipase A2Receptor as Target Antigen in Idiopathic Membranous NephropathyNew England Journal of Medicine, 2009
- A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2007
- A Randomized Pilot Trial Comparing Methylprednisolone Plus a Cytotoxic Agent Versus Synthetic Adrenocorticotropic Hormone in Idiopathic Membranous NephropathyAmerican Journal of Kidney Diseases, 2006
- Idiopathic Membranous Nephropathy: Outline and Rationale of a Treatment StrategyAmerican Journal of Kidney Diseases, 2005
- ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnosesNephrology Dialysis Transplantation, 2004
- Idiopathic membranous glomerulonephritisKidney International, 2001
- Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathyKidney International, 1999
- A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathyKidney International, 1995